Labcorp Holdings Inc. (LH)

Over the past six months, Labcorp's stock has increased by 26.69% over the last year, with a 28.21% increase between October 4, 2024, and October 3, 2025, reaching a 52-week high of $289.20 on October 1, 2025. Labcorp acquired BioReference Health's Oncology and Related Clinical Testing Businesses on September 15, 2025. On August 18, 2025, Labcorp launched the Lumipulse pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood test to aid in diagnosing Alzheimer's disease. Labcorp announced a collaboration with Roche on September 30, 2025, to advance digital pathology capabilities. Labcorp announced its second-quarter 2025 results on July 24, 2025, raising its full-year guidance, and announced its first-quarter 2025 results, updating its full-year guidance. Several analysts have maintained positive ratings and incrementally raised price targets for Labcorp.

The provided search results do not contain explicit information regarding the demand seasonality for Labcorp Holdings, Inc.'s products and services. However, demand might be influenced by factors such as flu seasons, healthcare spending cycles, and the pace of pharmaceutical research and development.

Labcorp Holdings, Inc. is a global life sciences company providing laboratory services to doctors, hospitals, pharmaceutical companies, researchers, and patients. It operates in the Healthcare sector, specifically in Medical Specialties, Health Care Services, and Diagnostics & Research industries. Labcorp's operations are divided into Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment offers routine and specialty testing services, including blood chemistry analyses, urinalyses, and advanced tests for specific diseases. The Biopharma Laboratory Services segment focuses on end-to-end drug development, medical device, and diagnostic development solutions. Labcorp also provides wellness services and leverages digital healthcare platforms.

Labcorp Holdings, Inc. has a significant global presence, serving clients in approximately 100 countries. The company's headquarters are located in Burlington, North Carolina, United States. Its Diagnostics Laboratories segment operates through a vast network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories.

Labcorp's brand reputation in the past year appears to be strong, marked by strategic collaborations, innovative product launches, and positive analyst sentiment. The launch of the first FDA-cleared blood test for Alzheimer's disease enhanced Labcorp's image as an innovator. The acquisition of BioReference Health's oncology testing businesses and the collaboration with Roche demonstrate Labcorp's commitment to expanding its services. Consistent financial performance contributes to a positive perception among investors, and analyst confidence indicates a favorable view of Labcorp's future prospects.

Labcorp Holdings, Inc. is primarily owned by institutional shareholders, who hold approximately 96.23% of the company's stock. Insiders own about 1.53%, and retail investors hold approximately 2.24%. The largest individual shareholder is Vanguard Group Inc., owning 9.88 million shares representing 11.89% of the company.